CNCR
Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

366
Loading...
Loading...
News
all
press releases
News Placeholder
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.
Stocktwits·2mo ago

Latest CNCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.